TY - JOUR
T1 - Inhaler competence in asthma
T2 - Common errors, barriers to use and recommended solutions
AU - Price, D.
AU - Bosnic-Anticevich, S.
AU - Briggs, A.
AU - Chrystyn, H.
AU - Rand, C.
AU - Scheuch, G.
AU - Bousquet, J.
N1 - Funding Information:
Jean Bousquet has received honoraria from the following organizations for his participation in scientific advisory boards, lectures and press conferences: Stallergènes, Actelion, Almirall, AstraZeneca, Chiesi, GSK, Merck, MSD, Novartis, OM Pharma, Sanofi-Aventis, Schering Plough, Teva, and Uriach. Member of GA 2 LEN (Global Allergy and Asthma European Network), supported by the Sixth EU Framework program for research, contract n° FOOD-CT-2004-506378.
Funding Information:
Sinthia Bosnic-Anticevich has no shares in any pharmaceutical companies. In the past five years she has provided consulting on the topic of inhaler device use to Pharmaceutical Society of Australia and the Pharmacy Guild of Australia. She has received research funding from the Australian Commonwealth Government Department of Health and the Australian Research Council .
PY - 2013/1
Y1 - 2013/1
N2 - Whilst the inhaled route is the first line administration method in the management of asthma, it is well documented that patients can have problems adopting the correct inhaler technique and thus receiving adequate medication. This applies equally to metered dose inhalers and dry powder inhalers and leads to poor disease control and increased healthcare costs. Reviews have highlighted these problems and the recent European Consensus Statement developed a call to action to seek solutions. This review takes forward the challenge of inhaler competence by highlighting the issues and suggesting potential solutions to these problems. The opportunity for technological innovation and educational interventions to reduce errors is highlighted, as well as the specific challenges faced by children. This review is intended as a policy document, as most issues faced by patients have not changed for half a century, and this situation should not be allowed to continue any longer. Future direction with respect to research, policy needs and practice, together with education requirements in inhaler technique are described.
AB - Whilst the inhaled route is the first line administration method in the management of asthma, it is well documented that patients can have problems adopting the correct inhaler technique and thus receiving adequate medication. This applies equally to metered dose inhalers and dry powder inhalers and leads to poor disease control and increased healthcare costs. Reviews have highlighted these problems and the recent European Consensus Statement developed a call to action to seek solutions. This review takes forward the challenge of inhaler competence by highlighting the issues and suggesting potential solutions to these problems. The opportunity for technological innovation and educational interventions to reduce errors is highlighted, as well as the specific challenges faced by children. This review is intended as a policy document, as most issues faced by patients have not changed for half a century, and this situation should not be allowed to continue any longer. Future direction with respect to research, policy needs and practice, together with education requirements in inhaler technique are described.
KW - Asthma
KW - Chronic obstructive pulmonary disease (COPD)
KW - Inhalers
UR - http://www.scopus.com/inward/record.url?scp=84871385237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871385237&partnerID=8YFLogxK
U2 - 10.1016/j.rmed.2012.09.017
DO - 10.1016/j.rmed.2012.09.017
M3 - Article
C2 - 23098685
AN - SCOPUS:84871385237
SN - 0954-6111
VL - 107
SP - 37
EP - 46
JO - Respiratory Medicine
JF - Respiratory Medicine
IS - 1
ER -